Adverum Biotechnologies I... (ADVM)
3.31
-0.27 (-7.54%)
At close: Apr 10, 2025, 3:59 PM
3.42
3.37%
Pre-market: Apr 11, 2025, 06:34 AM EDT
-7.54% (1D)
| Bid | 3.41 |
| Market Cap | 68.75M |
| Revenue (ttm) | -2.6M |
| Net Income (ttm) | -94.11M |
| EPS (ttm) | -5.95 |
| PE Ratio (ttm) | -0.56 |
| Forward PE | -1.02 |
| Analyst | Buy |
| Ask | 3.7 |
| Volume | 121,582 |
| Avg. Volume (20D) | 173,483 |
| Open | 3.58 |
| Previous Close | 3.58 |
| Day's Range | 3.20 - 3.65 |
| 52-Week Range | 3.07 - 12.24 |
| Beta | 1.09 |
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with U...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 121
Stock Exchange NASDAQ
Ticker Symbol ADVM
Website https://www.adverum.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 732.07% from the latest price.
Stock ForecastsNext Earnings Release
Adverum Biotechnologies Inc. is scheduled to release its earnings on Apr 25, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
